Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-labeled Girentuximab for Intraoperative Detection of ccRCC
NCT02497599Phase 1Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2015
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indium-111-DOTA-girentuximab-IRDye800CW in clear cell renal cell carcinoma (ccRCC), sponsored by Radboud University Medical Center. Primary endpoint: Fluorescent signal at time of surgery. Status: unknown.
02
Drugs
indium-111-DOTA-girentuximab-IRDye800CW
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02497599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497599.